Trial Profile
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Registrational; Therapeutic Use
- Sponsors Zymenex A/S
- 16 Feb 2023 According to a Chiesi Global Rare Diseases media release, the USA Food and Drug Administration (FDA) has approved Lamzede (velmanase alfa-tycv) for the treatment of non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and pediatric patients.
- 09 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2014 New trial record